FDA Brief

Warning letters Drugs

FDA warning letter to

Somerset Therapeutics Private Limited

High riskIssued Sep 4, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA cited Somerset Therapeutics' India plant for CGMP failures tied to a contaminated media fill and aseptic processing risks.

What happened

FDA inspected the Somerset Therapeutics drug manufacturing facility in Karnataka, India, from February 10 to 21, 2025. FDA found inadequate investigations of a September 2024 media fill with visible contamination, out-of-specification impurity results, and aborted air-sampler events. During the inspection, FDA also observed tape securing a component to the interior ceiling of an ISO 5 filling area; the tape detached during aseptic manufacture of an injection, and FDA found aseptic interventions, material transfers, and airflow studies deficient.

What FDA found

  1. Somerset did not thoroughly investigate unexplained batch failures or discrepancies, including a September 2024 media fill contamination, out-of-specification impurity results, and aborted air-sampler events.

    21 CFR 211.192
  2. Somerset did not maintain equipment used to control aseptic conditions; FDA observed tape securing a component to the interior ceiling of an ISO 5 area, and the tape detached during aseptic manufacture.

    21 CFR 211.42(c)(10)(vi)
  3. Somerset did not establish and follow adequate written procedures to prevent microbiological contamination and validate aseptic and sterilization processes, with deficiencies in interventions, material transfers, and airflow studies.

    21 CFR 211.113(b)
  4. Somerset did not submit a Field Alert Report within three working days after identifying cloudy vials in a September 2024 media fill; it submitted one only after the inspection.

    21 CFR 314.81(b)(1)(ii); section 505(k) of the FD&C Act

What FDA wants

FDA asks Somerset to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence; if corrective actions cannot be completed, it must give reasons and a schedule.

Who should pay attention

  • companies that rely on Somerset as a contract manufacturer
  • brands selling sterile injectables made at this site
  • quality teams responsible for supplier oversight and Field Alert reporting

This is a summary. Read the original letter on fda.gov.

Somerset Therapeutics Private Limited's FDA history

Recalls in the last 12 months

Mar 25 Class II SOMERSET THERAPEUTICS LLC
Drug
Dexamethasone Sodium Phosphate Injection, USP, 100 mg/ 10 mL, (10 mg/mL), 10x10 mL Multiple Dose Vials, Rx only, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873, NDC carton: 70069-025-10; NDC vial: 7006…
Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were above specs for these impurities: Dexamethasone Sodium Phosphate EP impurity G (Impurity RU 49336) and dexamethasone formate.
Dec 24, 2025 Class III SOMERSET THERAPEUTICS LLC
Drug
Cisatracurium Besylate Injection USP, 20 mg/10 mL*,(2 mg/mL), 10 x 10 mL Multiple-dose Vials per carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, 10mL Multiple-dose vial,…
Subpotent product:out of specification assay results observed during long term stability testing.
Dec 24, 2025 Class III SOMERSET THERAPEUTICS LLC
Drug
Cisatracurium Besylate Injection USP, 200mg/20mL*(10mg/mL), 10 x 20 mL Single-dose Vials per Carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, Single dose 20mL vial NDC 70…
Subpotent product:out of specification assay results observed during long term stability testing.
Dec 24, 2025 Class III SOMERSET THERAPEUTICS LLC
Drug
Cisatracurium Besylate Injection USP, 10 mg/5 mL* (2mg/mL), 10 x 5 mL Single-dose Vials per Carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, Single-dose 5 mL vial NDC 700…
Subpotent product:out of specification assay results observed during long term stability testing.

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk